Production (Stage)
Ondine Biomedical Inc.
OBIMF
$0.14
$0.00392.87%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.49M | 1.35M | 1.21M | 1.05M | 891.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.49M | 1.35M | 1.21M | 1.05M | 891.20K |
| Cost of Revenue | 531.10K | 507.60K | 482.10K | 427.40K | 370.40K |
| Gross Profit | 962.70K | 845.90K | 724.10K | 624.20K | 520.80K |
| SG&A Expenses | 8.03M | 7.27M | 6.48M | 6.89M | 7.26M |
| Depreciation & Amortization | 390.60K | 398.10K | 404.60K | 414.60K | 422.40K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.66M | 13.87M | 11.99M | 11.96M | 11.86M |
| Operating Income | -14.17M | -12.51M | -10.78M | -10.91M | -10.97M |
| Income Before Tax | -13.92M | -12.26M | -10.54M | -10.64M | -10.68M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.92 | -12.26 | -10.54 | -10.64 | -10.68 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.92M | -12.26M | -10.54M | -10.64M | -10.68M |
| EBIT | -14.17M | -12.51M | -10.78M | -10.91M | -10.97M |
| EBITDA | -14.02M | -12.37M | -10.64M | -10.76M | -10.82M |
| EPS Basic | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| EPS Diluted | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| Average Basic Shares Outstanding | 1.10B | 990.18M | 881.95M | 835.20M | 788.45M |
| Average Diluted Shares Outstanding | 1.10B | 990.18M | 881.95M | 835.20M | 788.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |